Origin Endoscopy

Origin Endoscopy is a private, pre-revenue biotech firm pioneering a proprietary hydrogel platform for enhanced drug delivery during endoscopic procedures. The company's core innovation is a hydrogel that facilitates ultrafast adhesion and submucosal injection, potentially improving the administration of therapeutics, dyes, or marking agents in the GI tract. While still in a pre-clinical or early development stage, its technology addresses a significant need for more reliable and efficient delivery methods in interventional gastroenterology. The company appears to be in a seed or venture-backed phase, building its technology platform and engaging with potential partners.

Proprietary multipurpose hydrogel engineered for ultrafast bio-adhesion and submucosal injection, enabling stable tissue lifting and localized drug delivery during endoscopic procedures.

Competes against standard-of-care fluids (saline, hyaluronic acid) and could face future competition from other biomaterial startups or large medtech firms with existing endoscopic sales channels. Differentiation hinges on proving superior adhesion speed and duration.